Overview

The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy of 3 different dosing regimens of enoxaparin in achieving adequate antithrombotic aFXa levels in critically ill patients. The relationship between appearance of DVT and antithrombotic aFXa levels will also be assessed and risk factors associated with inadequate aFXa levels under standard enoxaparin dosages will be searched for.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shaare Zedek Medical Center
Treatments:
Enoxaparin
Vasoconstrictor Agents
Criteria
Inclusion Criteria:

All critically ill patients, aged ≥18 years, with a predicted requirement for mechanical
ventilation of more than 3 days and for whom venous thromboembolic prophylaxis is
indicated.

-

Exclusion Criteria:

1. Patients requiring full anticoagulation

2. Administration of unfractionated heparin in the 8hrs preceding study entry

3. Existing contraindication to prophylactic dose of enoxaparin.

4. Platelets < 75,000

5. Significant renal failure (creatinine clearance <30 ml/min/m2) [39]

6. BMI > 30

7. INR > 1.7

8. Any conditions precluding treatment in the opinion of the primary physician

9. Patient /surrogate refusal

-